CA2197050A1 - Anti-cancer agents derived from fertilized incubated shell eggs - Google Patents
Anti-cancer agents derived from fertilized incubated shell eggsInfo
- Publication number
- CA2197050A1 CA2197050A1 CA 2197050 CA2197050A CA2197050A1 CA 2197050 A1 CA2197050 A1 CA 2197050A1 CA 2197050 CA2197050 CA 2197050 CA 2197050 A CA2197050 A CA 2197050A CA 2197050 A1 CA2197050 A1 CA 2197050A1
- Authority
- CA
- Canada
- Prior art keywords
- egg
- fertilized
- incubated
- composition
- eggs
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Fertilized incubated shell eggs, e.g. avian eggs and in particular hens eggs, may be used to produce a composition which is useful in the prevention and treatment of cancer. The compositions are substantially non-toxic and may be used in conjunction with conventional cancer treatments such as radiation and chemotherapy. Preferably, the compositions of the present invention contain fertilized hens' eggs which have been incubated for about 8 to 10 days. The compositions may be administered into the gastrointestinal tract of a patient in a variety of forms or may be administered by injection.
Description
, ANTI-CANCER AGENTS DERIVED FROM
FERTT~ T7.Fn INCUBATED SHELL EGGS
The present invention relates to the use of fertilized incubated shell eggs in the treatment and prevention of cancer, and to compositions comprising such eggs or extracts thereof.
The toxic effects of conventional cancer treatments such as chemotherapy and radiation are well known. Frequently, patients in the end stages of cancer are too weak to withstand the toxicity of such treatments, thus limiting treatment options for such patients.
Therefore, the disadvantage exists that the toxicity of conventional cancer treatments limits their efficacy.
SUMMARY OF THE INVENTION
Fertilized eggs, and even fertilized partially incubated eggs, have been 20 used in the past as a foodstuff. It is also known that fertilized incubated shell eggs have libido or testosterone enhancing properties and are therefore used to treat disorders of sexual function.
However, the inventor has surprisingly found that fertilized incubated shell eggs have anti-cancer activity and may be used in the prevention and 25 treatment of cancer. Compositions according to the present invention cont~inin~ fertilized incubated shell eggs are non-toxic and may be used in combination with other cancer treatments such as radiation and/or chemotherapy. Compositions according to the present invention are particularly useful in the treatment of end stage cancer, and in cases where conventional treatments such as radiation and chemotherapy have failed.
One object of the present invention is to provide a method of treatment of the human or non-human m~mm~ n body to treat or prevent cancer, said method comprising ~dmini~tering to said body a therapeutic agent derived 5 from fertilized, incubated shell eggs.
Another object of the present invention is to provide the use of fertilized incubated shell eggs for the manufacture of an agent for use in treatment of cancer in a human or non-human m~mm~ n body.
Yet another object of the present invention is to provide the use of 10 fertilized incubated shell eggs for the manufacture of an agent for use in prevention of cancer in a human or non-human m~mm~ n body.
Yet another object of the present invention is to provide a novel therapeutic composition comprising an amount of dried fertilized incubated shell eggs or a component thereof effective to treat or prevent cancer, 15 optionally together with one or more physiologically tolerable carriers or excipients.
Yet another object of the present invention is to provide a process for the preparation of an anti-cancer agent, the process comprising incubating fertilized shell eggs into the blastodermal to protoembryonic stage (e.g. for 20 2 to 15, preferably about 10 days in the case of hens eggs) and freeze dryingthe shell contents or a component thereof having anti-cancer activity, for example the yoLk from which the surrolln~lin~ albumin has been removed.
In one aspect, the present invention provides a composition, comprising: an amount of an egg product effective to prevent or treat cancer, 25 the egg product being selected from the group comprising dried fertilized incubated shell egg and components thereof; and one or more physiologically tolerable carriers or excipients.
In another aspect, the present invention provides the use of fertilized _ 3 incubated shell egg to treat or prevent cancer in a m~mm~l.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The inventor has found that anti-cancer action is possessed by 5 fertilized and incubated eggs, whereas unfertilized and/or unincubated eggs do not appear to have this activity. Although the reason for the anti-cancer activity of fertilized incubated shell eggs is not clear, it is believed to result from the production of active factors in the transformation of the egg yolk during embryogenesis.
By a shell egg is meant an ~nim~l egg having an opaque shell, preferably a bird or reptile egg. More preferably, the shell eggs used in the present invention are avian eggs, especially those from birds bred for egg production, for example hens, geese, ducks, quail, turkeys, ostriches, phe~nt~, pigeons and the like. Mostpreferably, the shell eggs used in the 15 present invention are hens' eggs.
Eggs produced for human consumption are typically either unfertilized or majoritively unfertilized. Fertilized eggs which may inadvertently be presented for human consumption are generally unincubated eggs or eggs which have been incubated only for 1 or 2 days.
The eggs used according to the invention are preferably in the blastodermal and subsequent preembryonic to protoembryonic stages in which yolk transformation has begun, but the organs of the embryo are barely if at all discernible. This corresponds essentially to the subembryonic liquid stage of embryogenesis, generally 3 to 14 days incubation for a hen's egg, or the 25 period up to the acceleration of calcium uptake by the embryo, which typically occurs after about 15 days incubation for the hen's egg.
In the case of fertilized hens' eggs used according to the invention, the incubation period is preferably up to about 15 days, for example 2 to 15 days, more preferably about 3 to 12 days, particularly preferably about 5 to 10 days, and most preferably about 8, 9 or 10 days. Eggs incubated for such periods would generally be considered unfit for human consumption due to the degree of transformation of the yolk that has occurred and, for the upper 5 limit, due to the presence of an embryo with visible organs.
Although the eggs used in the present invention are preferably in the subembryonic liquid stage of embryogenesis, in which the organs of the embryo are not clearly discernible, this is not necessarily the case. For example, eggs in which the embryo is has at least partially developed or is 10 ready to hatch may also be used according to the present invention.
Examples of such eggs include hen or duck eggs which have been incubated for greater than 15 days, preferably about 18 days.
Therapeutic agents according to the present invention may be s~lmini~tered to humans and other m~mm~l~ by a variety of methods, for 15 example into the gastrointestinal tract (rectally or more preferably orally) or by injection.
For oral ~lmini~tration according to the present invention, it is of course feasible to ~(lmini~ter the egg contents without any extensive preparation, for example the whole egg or egg yolk whisked into a glass of 20 milk.
However, it is preferred that fertilized, incubated eggs for gastrointestinal ~-lmini.~tration be in freeze dried form. Freeze dried egg is easily mixed with other ingredients to form a composition and has a shelf life which facilitates manufacture, pack~in~, transport and storage of 25 compositions according to the invention.
The dried egg may be prepared for example by freeze drying the whole uncooked contents from within the egg shell. Alternatively, the contents may be divided to remove some or all of the albumin and if desired some or all of the macroscopic structures within and surro~ln~lin~ the yolk, for example membranes, blood vessels and embryo. Nevertheless, for general ease of preparation, either the entire shell content or the yolk fraction of such contents divided physically into yolk and albumin, for example by pouring 5 off the albumin, are preferably used to produce the compositions of the invention.
The freeze dried product produced in this way is low in cholesterol and, as long as the eggs' surfaces are sterilized before removal of the contents there should be no health concerns relating to the ingestion of the 10 product. Nonetheless, the eggs preferably derive from a salmonella free flock and thus fertilized hens eggs deriving from Norway, Sweden, Finland, New 7e~1~n~1 and Malta are particularly preferred.
Compositions of the present invention for gastrointestinal ~clmini~tration are preferably in pulverulent form and optionally include other 15 components serving for example to enhance or mask flavour or to facilitate dispersion of the egg powder in an aqueous fluid for oral ~lmini~tration.
The compositions can however contain conventional pharmaceutical carriers or excipients and may be presented in standard ~lmini~tration forms for oral or rectal ~-lmini~tration, for example powders, tablets, coated tablets, 20 capsules, suppositories, etc.
Examples of preferred additives include the vitamins and minerals of conventional daily food supplement compositions, sweeteners such as saccharides, carotenes, folic acid, citrates, plant flavourings such as ginseng,vitamin Bl2, vitamin Bl (e.g. t~i~mine), vitamin C, vitamin E
2s (e.g. c~-tocopherol)"~-carotene, folic acid, glucose, fructose, sodium and potassium citrates, gelatin, glycerine, silica (silicon dioxide), silicium dioxide, magnesium chloride, zinc oxide, and extracts, oils or powders derived from ginseng, aniseed, rosemary, peppermint, hops, camomile, 2~ 97050 thyme, clove and fennel.
The egg powder preferably is present in the above compositions at about 30 to 90% by weight, preferably about 70 to 80% by weight, more preferably about 75 % by weight of the composition.
In another preferred embodiment of the present invention, compositions are provided cont~inin~ fertilized incubated egg in amounts greater than 90%
by weight, including fertilized incubated egg in pure or substantially pure form. The fertilized incubated egg used in these preferred forms may be prepared using either the entire shell content of fertilized eggs or the yoL~
10 fraction only.
More preferably, the present invention provides compositions cont~inin~ fertilized incubated egg in amounts greater than 95% by weight, and most preferably greater than about 96% by weight. Such compositions may contain any of the additives which may be used in compositions 15 cont~inin~ egg powder in the range of 30 to 90% by weight. However, these compositions preferably contain little or no flavour enhancing ingredients, and most preferably do not contain any flavour enhancing ingredients.
One particularly preferred composition for gastrointestinal ~dmini~tration according to this embodiment comprises about 96% by weight 20 fertilized incubated egg powder and contains as additives potassium citrate, sodium citrate, tx-tocopherol, silicon dioxide, gelatin and glycerine. Such a composition is preferably in the form of a powder, tablet, coated tablet, capsule, suppository, or any other convenient form, most preferably a capsule, each capsule preferably cont~inin~ about 450 mg of composition.
Furthermore, the fertilized incubated egg according to the present invention may be gastrointestinally ~dmini~tered in pure form without any additives. In this case, the fertilized incubated egg may be in any convenient form, including the forms mentioned above.
In another preferred embodiment, the present invention provides food and beverage products for oral ~-lmini~tration cont~ining fertilized incubated egg. The fertilized incubated egg may be present in such food and beverage products either in pure form or in the form of a composition. The inventor 5 has found the fertilized incubated egg, particularly in powder form, to be inert and stable, both in pure form and in the form the compositions disclosed herein. Therefore, the fertilized incubated egg of the present invention may be added to a wide range of food and beverage products, thus providing the benefits of fertilized incubated egg in a convenient and pleasant 10 tasting form.
For example, the fertilized incubated egg may preferably be presented in a convenient snack food form to be consumed at least once a day. Such snack foods include chocolate bars, candy bars, energy bars and granola bars. The addition of small amounts of fertilized incubated egg to foods, for 15 example on the order of from about 3 to about 5 g, would not subst~nti~lly affect their taste.
The fertilized incubated egg may also be incorporated into a wide range of other food products which may be consumed hot or cold.
Alternatively, the fertilized incubate egg in pure form or in the form of a 20 composition may be packaged in powdered or any other convenient form for use as a food additive, the user ~ lin~ measured amounts of the additive to his or her meals.
Preferred beverage products cont~inin~ the fertilized incubated egg of the present invention include ready to consume beverage products and 25 beverage concentrates in liquid and solid form to be mixed with water. Most preferred beverage products include milk shake type drinks, energy drinks, mineral replacement drinks as used by athletes, juices, and flavoured crystals or powder to be mixed with water. As with food products, a small, measured, amount of fertilized incubated egg powder, for example 3 to 5 g, would not subst~nti~lly affect the flavour of the beverage product.
As mentioned above, the present invention also includes within its scope injectable compositions cont~inin~ fertilized incubated eggs. As in the 5 case of gastrointestinally ~dmini~tered compositions, injectable compositions may be prepared in which the egg contents are used directly without extensive preparation. For example, one injectable composition of the present invention is prepared by breaking open a fertilized hen's egg which has been incubated for 8 or 9 days and ~ddin~ up to about 0.5 chlorbutanol 10 to the egg contents as a preservative. The resulting mixture is then boiled and filtered to yield an injectable composition.
It is to be appreciated that numerous other injectable compositions may also be prepared, for example from freeze dried fertilized incubated eggs as discussed above. The injectable compositions according to the present 15 invention may also comprise pharmaceutically acceptable additives and carriers, including some of those listed above.
In one preferred embodiment of the present invention, fertilized incubated egg in any of the forms described above is ~lmini.stered to a patient concurrently with a high vitamin diet and/or a vitamin supplemented 20 diet. The diet preferably includes subst~nti~l amounts of raw fruits and vegetables, wheat germ, vegetable juices and milk. Vitamin supplements preferably include a vitamin B complex.
The compositions according to the present invention are preferably ~dmini~tered to cancer patients having malignant tumours which may or may 25 not have formed secondary (metastatic) growths in other parts of the body via the blood or lymph system. One major advantage of the compositions of the present invention is that they are non-toxic in comparison to conventional treatments such as surgery, chemotherapy and radiation. This permits the g compositions of the present invention to be used in combination with conventional forms of treatment without the danger of further weakening the patient. Furthermore, treatment with the compositions may continue for an extended period of time at relatively high doses without c~ in a toxic 5 reaction in the patient. The compositions of the present invention may also be used in patients in the end stages of cancer who may be too frail to endure further treatment by conventional means, or for whom conventional treatments would provide no further benefit.
Although the compositions of the present invention are subst~n~i~lly 10 non-toxic, caution must be exercised in ~lmini~tering the compositions due to the risk of allergic reactions in patients having egg allergies.
Due to the non-toxicity of the compositions of the present invention, patients may preferably be treated with large doses of the compositions for an extended period of time. Preferred doses comprise the equivalent of from 15 about 10 to about 50 fertilized incubated eggs per day, more preferably from about 15 to about 35 fertilized incubated eggs per day, and most preferably from about 20 to 30 fertilized incubated eggs per day. In some cases, the dosage may be limited to avoid causing an allergic reaction in a patient.
Treatment for a period of about two months is typically required before 20 patients experience a noticeable decrease in the number and size of tumours.
Once treatment has commenced, it is preferably continued for an indefinite period. Even after total disappearance of tumours, it is preferred that treatment be continued in order to prevent the cancer from returning.
Although the compositions of the present invention are preferably used 25 to treat patients having cancerous tumours, it is to be appreciated that the compositions may also be used on a preventative basis in healthy persons who have never had cancer or in persons whose cancers have been successfully treated.
.
Although the compositions of the present invention have been described above as being useful for treating cancer in humans, it is to be understood that the compositions may be used to treat cancer in non-human ~nim~
preferably m~mm~
Although the invention has been described in connection with certain preferred embodiments, it is not intended to be limited thereto. Rather, it is intended that the invention cover all alternate embodiments as may be within the scope of the following claims. The invention also includes all embodiments which are functional or mechanical equivalents of the specific 10 embodiments and features that have been described herein.
It will be further understood that, although various features of the invention have been described with respect to one or another of the embodiments of the invention, the various features and embodiments of the invention may be combined or used in conjunction with other features and 15 embodiments of the invention as described herein.
FERTT~ T7.Fn INCUBATED SHELL EGGS
The present invention relates to the use of fertilized incubated shell eggs in the treatment and prevention of cancer, and to compositions comprising such eggs or extracts thereof.
The toxic effects of conventional cancer treatments such as chemotherapy and radiation are well known. Frequently, patients in the end stages of cancer are too weak to withstand the toxicity of such treatments, thus limiting treatment options for such patients.
Therefore, the disadvantage exists that the toxicity of conventional cancer treatments limits their efficacy.
SUMMARY OF THE INVENTION
Fertilized eggs, and even fertilized partially incubated eggs, have been 20 used in the past as a foodstuff. It is also known that fertilized incubated shell eggs have libido or testosterone enhancing properties and are therefore used to treat disorders of sexual function.
However, the inventor has surprisingly found that fertilized incubated shell eggs have anti-cancer activity and may be used in the prevention and 25 treatment of cancer. Compositions according to the present invention cont~inin~ fertilized incubated shell eggs are non-toxic and may be used in combination with other cancer treatments such as radiation and/or chemotherapy. Compositions according to the present invention are particularly useful in the treatment of end stage cancer, and in cases where conventional treatments such as radiation and chemotherapy have failed.
One object of the present invention is to provide a method of treatment of the human or non-human m~mm~ n body to treat or prevent cancer, said method comprising ~dmini~tering to said body a therapeutic agent derived 5 from fertilized, incubated shell eggs.
Another object of the present invention is to provide the use of fertilized incubated shell eggs for the manufacture of an agent for use in treatment of cancer in a human or non-human m~mm~ n body.
Yet another object of the present invention is to provide the use of 10 fertilized incubated shell eggs for the manufacture of an agent for use in prevention of cancer in a human or non-human m~mm~ n body.
Yet another object of the present invention is to provide a novel therapeutic composition comprising an amount of dried fertilized incubated shell eggs or a component thereof effective to treat or prevent cancer, 15 optionally together with one or more physiologically tolerable carriers or excipients.
Yet another object of the present invention is to provide a process for the preparation of an anti-cancer agent, the process comprising incubating fertilized shell eggs into the blastodermal to protoembryonic stage (e.g. for 20 2 to 15, preferably about 10 days in the case of hens eggs) and freeze dryingthe shell contents or a component thereof having anti-cancer activity, for example the yoLk from which the surrolln~lin~ albumin has been removed.
In one aspect, the present invention provides a composition, comprising: an amount of an egg product effective to prevent or treat cancer, 25 the egg product being selected from the group comprising dried fertilized incubated shell egg and components thereof; and one or more physiologically tolerable carriers or excipients.
In another aspect, the present invention provides the use of fertilized _ 3 incubated shell egg to treat or prevent cancer in a m~mm~l.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
The inventor has found that anti-cancer action is possessed by 5 fertilized and incubated eggs, whereas unfertilized and/or unincubated eggs do not appear to have this activity. Although the reason for the anti-cancer activity of fertilized incubated shell eggs is not clear, it is believed to result from the production of active factors in the transformation of the egg yolk during embryogenesis.
By a shell egg is meant an ~nim~l egg having an opaque shell, preferably a bird or reptile egg. More preferably, the shell eggs used in the present invention are avian eggs, especially those from birds bred for egg production, for example hens, geese, ducks, quail, turkeys, ostriches, phe~nt~, pigeons and the like. Mostpreferably, the shell eggs used in the 15 present invention are hens' eggs.
Eggs produced for human consumption are typically either unfertilized or majoritively unfertilized. Fertilized eggs which may inadvertently be presented for human consumption are generally unincubated eggs or eggs which have been incubated only for 1 or 2 days.
The eggs used according to the invention are preferably in the blastodermal and subsequent preembryonic to protoembryonic stages in which yolk transformation has begun, but the organs of the embryo are barely if at all discernible. This corresponds essentially to the subembryonic liquid stage of embryogenesis, generally 3 to 14 days incubation for a hen's egg, or the 25 period up to the acceleration of calcium uptake by the embryo, which typically occurs after about 15 days incubation for the hen's egg.
In the case of fertilized hens' eggs used according to the invention, the incubation period is preferably up to about 15 days, for example 2 to 15 days, more preferably about 3 to 12 days, particularly preferably about 5 to 10 days, and most preferably about 8, 9 or 10 days. Eggs incubated for such periods would generally be considered unfit for human consumption due to the degree of transformation of the yolk that has occurred and, for the upper 5 limit, due to the presence of an embryo with visible organs.
Although the eggs used in the present invention are preferably in the subembryonic liquid stage of embryogenesis, in which the organs of the embryo are not clearly discernible, this is not necessarily the case. For example, eggs in which the embryo is has at least partially developed or is 10 ready to hatch may also be used according to the present invention.
Examples of such eggs include hen or duck eggs which have been incubated for greater than 15 days, preferably about 18 days.
Therapeutic agents according to the present invention may be s~lmini~tered to humans and other m~mm~l~ by a variety of methods, for 15 example into the gastrointestinal tract (rectally or more preferably orally) or by injection.
For oral ~lmini~tration according to the present invention, it is of course feasible to ~(lmini~ter the egg contents without any extensive preparation, for example the whole egg or egg yolk whisked into a glass of 20 milk.
However, it is preferred that fertilized, incubated eggs for gastrointestinal ~-lmini.~tration be in freeze dried form. Freeze dried egg is easily mixed with other ingredients to form a composition and has a shelf life which facilitates manufacture, pack~in~, transport and storage of 25 compositions according to the invention.
The dried egg may be prepared for example by freeze drying the whole uncooked contents from within the egg shell. Alternatively, the contents may be divided to remove some or all of the albumin and if desired some or all of the macroscopic structures within and surro~ln~lin~ the yolk, for example membranes, blood vessels and embryo. Nevertheless, for general ease of preparation, either the entire shell content or the yolk fraction of such contents divided physically into yolk and albumin, for example by pouring 5 off the albumin, are preferably used to produce the compositions of the invention.
The freeze dried product produced in this way is low in cholesterol and, as long as the eggs' surfaces are sterilized before removal of the contents there should be no health concerns relating to the ingestion of the 10 product. Nonetheless, the eggs preferably derive from a salmonella free flock and thus fertilized hens eggs deriving from Norway, Sweden, Finland, New 7e~1~n~1 and Malta are particularly preferred.
Compositions of the present invention for gastrointestinal ~clmini~tration are preferably in pulverulent form and optionally include other 15 components serving for example to enhance or mask flavour or to facilitate dispersion of the egg powder in an aqueous fluid for oral ~lmini~tration.
The compositions can however contain conventional pharmaceutical carriers or excipients and may be presented in standard ~lmini~tration forms for oral or rectal ~-lmini~tration, for example powders, tablets, coated tablets, 20 capsules, suppositories, etc.
Examples of preferred additives include the vitamins and minerals of conventional daily food supplement compositions, sweeteners such as saccharides, carotenes, folic acid, citrates, plant flavourings such as ginseng,vitamin Bl2, vitamin Bl (e.g. t~i~mine), vitamin C, vitamin E
2s (e.g. c~-tocopherol)"~-carotene, folic acid, glucose, fructose, sodium and potassium citrates, gelatin, glycerine, silica (silicon dioxide), silicium dioxide, magnesium chloride, zinc oxide, and extracts, oils or powders derived from ginseng, aniseed, rosemary, peppermint, hops, camomile, 2~ 97050 thyme, clove and fennel.
The egg powder preferably is present in the above compositions at about 30 to 90% by weight, preferably about 70 to 80% by weight, more preferably about 75 % by weight of the composition.
In another preferred embodiment of the present invention, compositions are provided cont~inin~ fertilized incubated egg in amounts greater than 90%
by weight, including fertilized incubated egg in pure or substantially pure form. The fertilized incubated egg used in these preferred forms may be prepared using either the entire shell content of fertilized eggs or the yoL~
10 fraction only.
More preferably, the present invention provides compositions cont~inin~ fertilized incubated egg in amounts greater than 95% by weight, and most preferably greater than about 96% by weight. Such compositions may contain any of the additives which may be used in compositions 15 cont~inin~ egg powder in the range of 30 to 90% by weight. However, these compositions preferably contain little or no flavour enhancing ingredients, and most preferably do not contain any flavour enhancing ingredients.
One particularly preferred composition for gastrointestinal ~dmini~tration according to this embodiment comprises about 96% by weight 20 fertilized incubated egg powder and contains as additives potassium citrate, sodium citrate, tx-tocopherol, silicon dioxide, gelatin and glycerine. Such a composition is preferably in the form of a powder, tablet, coated tablet, capsule, suppository, or any other convenient form, most preferably a capsule, each capsule preferably cont~inin~ about 450 mg of composition.
Furthermore, the fertilized incubated egg according to the present invention may be gastrointestinally ~dmini~tered in pure form without any additives. In this case, the fertilized incubated egg may be in any convenient form, including the forms mentioned above.
In another preferred embodiment, the present invention provides food and beverage products for oral ~-lmini~tration cont~ining fertilized incubated egg. The fertilized incubated egg may be present in such food and beverage products either in pure form or in the form of a composition. The inventor 5 has found the fertilized incubated egg, particularly in powder form, to be inert and stable, both in pure form and in the form the compositions disclosed herein. Therefore, the fertilized incubated egg of the present invention may be added to a wide range of food and beverage products, thus providing the benefits of fertilized incubated egg in a convenient and pleasant 10 tasting form.
For example, the fertilized incubated egg may preferably be presented in a convenient snack food form to be consumed at least once a day. Such snack foods include chocolate bars, candy bars, energy bars and granola bars. The addition of small amounts of fertilized incubated egg to foods, for 15 example on the order of from about 3 to about 5 g, would not subst~nti~lly affect their taste.
The fertilized incubated egg may also be incorporated into a wide range of other food products which may be consumed hot or cold.
Alternatively, the fertilized incubate egg in pure form or in the form of a 20 composition may be packaged in powdered or any other convenient form for use as a food additive, the user ~ lin~ measured amounts of the additive to his or her meals.
Preferred beverage products cont~inin~ the fertilized incubated egg of the present invention include ready to consume beverage products and 25 beverage concentrates in liquid and solid form to be mixed with water. Most preferred beverage products include milk shake type drinks, energy drinks, mineral replacement drinks as used by athletes, juices, and flavoured crystals or powder to be mixed with water. As with food products, a small, measured, amount of fertilized incubated egg powder, for example 3 to 5 g, would not subst~nti~lly affect the flavour of the beverage product.
As mentioned above, the present invention also includes within its scope injectable compositions cont~inin~ fertilized incubated eggs. As in the 5 case of gastrointestinally ~dmini~tered compositions, injectable compositions may be prepared in which the egg contents are used directly without extensive preparation. For example, one injectable composition of the present invention is prepared by breaking open a fertilized hen's egg which has been incubated for 8 or 9 days and ~ddin~ up to about 0.5 chlorbutanol 10 to the egg contents as a preservative. The resulting mixture is then boiled and filtered to yield an injectable composition.
It is to be appreciated that numerous other injectable compositions may also be prepared, for example from freeze dried fertilized incubated eggs as discussed above. The injectable compositions according to the present 15 invention may also comprise pharmaceutically acceptable additives and carriers, including some of those listed above.
In one preferred embodiment of the present invention, fertilized incubated egg in any of the forms described above is ~lmini.stered to a patient concurrently with a high vitamin diet and/or a vitamin supplemented 20 diet. The diet preferably includes subst~nti~l amounts of raw fruits and vegetables, wheat germ, vegetable juices and milk. Vitamin supplements preferably include a vitamin B complex.
The compositions according to the present invention are preferably ~dmini~tered to cancer patients having malignant tumours which may or may 25 not have formed secondary (metastatic) growths in other parts of the body via the blood or lymph system. One major advantage of the compositions of the present invention is that they are non-toxic in comparison to conventional treatments such as surgery, chemotherapy and radiation. This permits the g compositions of the present invention to be used in combination with conventional forms of treatment without the danger of further weakening the patient. Furthermore, treatment with the compositions may continue for an extended period of time at relatively high doses without c~ in a toxic 5 reaction in the patient. The compositions of the present invention may also be used in patients in the end stages of cancer who may be too frail to endure further treatment by conventional means, or for whom conventional treatments would provide no further benefit.
Although the compositions of the present invention are subst~n~i~lly 10 non-toxic, caution must be exercised in ~lmini~tering the compositions due to the risk of allergic reactions in patients having egg allergies.
Due to the non-toxicity of the compositions of the present invention, patients may preferably be treated with large doses of the compositions for an extended period of time. Preferred doses comprise the equivalent of from 15 about 10 to about 50 fertilized incubated eggs per day, more preferably from about 15 to about 35 fertilized incubated eggs per day, and most preferably from about 20 to 30 fertilized incubated eggs per day. In some cases, the dosage may be limited to avoid causing an allergic reaction in a patient.
Treatment for a period of about two months is typically required before 20 patients experience a noticeable decrease in the number and size of tumours.
Once treatment has commenced, it is preferably continued for an indefinite period. Even after total disappearance of tumours, it is preferred that treatment be continued in order to prevent the cancer from returning.
Although the compositions of the present invention are preferably used 25 to treat patients having cancerous tumours, it is to be appreciated that the compositions may also be used on a preventative basis in healthy persons who have never had cancer or in persons whose cancers have been successfully treated.
.
Although the compositions of the present invention have been described above as being useful for treating cancer in humans, it is to be understood that the compositions may be used to treat cancer in non-human ~nim~
preferably m~mm~
Although the invention has been described in connection with certain preferred embodiments, it is not intended to be limited thereto. Rather, it is intended that the invention cover all alternate embodiments as may be within the scope of the following claims. The invention also includes all embodiments which are functional or mechanical equivalents of the specific 10 embodiments and features that have been described herein.
It will be further understood that, although various features of the invention have been described with respect to one or another of the embodiments of the invention, the various features and embodiments of the invention may be combined or used in conjunction with other features and 15 embodiments of the invention as described herein.
Claims (16)
1. A composition, comprising:
an amount of an egg product effective to prevent or treat cancer, the egg product being selected from the group comprising dried fertilized incubated shell egg and components thereof; and one or more physiologically tolerable carriers or excipients.
an amount of an egg product effective to prevent or treat cancer, the egg product being selected from the group comprising dried fertilized incubated shell egg and components thereof; and one or more physiologically tolerable carriers or excipients.
2. The composition of claim 1, wherein said shell egg is an avian egg.
3. The composition of claim 2, wherein said avian egg is a hens egg.
4. The composition of claim 1, wherein said egg product comprises a freeze dried shell egg yolk.
5. The composition of claim 5, wherein said freeze dried shell egg yolk comprises a freeze dried hens egg yolk.
6. The composition of claim 1, wherein said shell egg is incubated to the blastodermal to protoembryonic stage.
7. The composition of claim 3, wherein said hens egg is incubated for a period of from about 8 to about 10 days.
8. The composition of claim 7, wherein said composition contains greater than about 90% by weight of said egg product.
9. The composition of claim 8, wherein said composition comprises greater than about 95% by weight of said egg product.
10. The composition of claim 9, wherein said composition comprises about 96% by weight of said egg product.
11. The use of fertilized incubated shell egg to treat or prevent cancer in a mammal.
12. The use of claim 11, wherein said fertilized incubated shell egg is freeze dried.
13 The use of claim 12, wherein said fertilized incubated shell egg is an avian egg.
14. The use of claim 13, wherein said avian egg is a hens egg.
15. The use of claim 14, wherein said hens egg is incubated for about 10 days.
16. The use of claim 11, wherein said mammal is human.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2197050 CA2197050A1 (en) | 1997-02-07 | 1997-02-07 | Anti-cancer agents derived from fertilized incubated shell eggs |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA 2197050 CA2197050A1 (en) | 1997-02-07 | 1997-02-07 | Anti-cancer agents derived from fertilized incubated shell eggs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2197050A1 true CA2197050A1 (en) | 1998-08-07 |
Family
ID=4159872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA 2197050 Abandoned CA2197050A1 (en) | 1997-02-07 | 1997-02-07 | Anti-cancer agents derived from fertilized incubated shell eggs |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2197050A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2073822A1 (en) * | 2006-10-12 | 2009-07-01 | United Paragon Associates Inc. | Processes for preparing fertilized egg components |
| WO2009115429A1 (en) * | 2008-03-19 | 2009-09-24 | Joan Cunill Aixela | Food preparation and pharmaceutical composition containing an embryonic extract |
| WO2013053503A1 (en) | 2011-10-13 | 2013-04-18 | Cunill Aixela Juan | Egg preparation with regenerating, analgesic and/or anti-inflammatory properties |
| US9999654B2 (en) | 2012-09-19 | 2018-06-19 | Sc Hipocrate 2002 Serv Srl | Composition with increased bioavailability of orally administered embryo-peptides and process for its obtainment |
| EP3771345A1 (en) * | 2019-07-29 | 2021-02-03 | HatchTech Group B.V. | Use of chicken embryo meat |
-
1997
- 1997-02-07 CA CA 2197050 patent/CA2197050A1/en not_active Abandoned
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2073822A1 (en) * | 2006-10-12 | 2009-07-01 | United Paragon Associates Inc. | Processes for preparing fertilized egg components |
| EP2073822A4 (en) * | 2006-10-12 | 2010-04-14 | United Paragon Associates Inc | Processes for preparing fertilized egg components |
| AU2007312906B2 (en) * | 2006-10-12 | 2013-06-27 | United Paragon Associates Inc. | Processes for preparing fertilized egg components |
| WO2009115429A1 (en) * | 2008-03-19 | 2009-09-24 | Joan Cunill Aixela | Food preparation and pharmaceutical composition containing an embryonic extract |
| ES2337537A1 (en) * | 2008-03-19 | 2010-04-26 | Joan Cunill Aixela | Food preparation and pharmaceutical composition containing an embryonic extract |
| WO2013053503A1 (en) | 2011-10-13 | 2013-04-18 | Cunill Aixela Juan | Egg preparation with regenerating, analgesic and/or anti-inflammatory properties |
| AU2012323427B2 (en) * | 2011-10-13 | 2015-08-27 | Ovivity Group S.L. | Egg preparation with regenerating, analgesic and/or anti-inflammatory properties |
| RU2585049C2 (en) * | 2011-10-13 | 2016-05-27 | Овивити Груп, С.Л. | Preparation from eggs with regenerative, analgesic and anti-inflammatory properties |
| US9717764B2 (en) | 2011-10-13 | 2017-08-01 | Ovivity Group, S.L. | Egg preparation with regenerating, analgesic and/or anti-inflammatory properties |
| US9999654B2 (en) | 2012-09-19 | 2018-06-19 | Sc Hipocrate 2002 Serv Srl | Composition with increased bioavailability of orally administered embryo-peptides and process for its obtainment |
| EP3771345A1 (en) * | 2019-07-29 | 2021-02-03 | HatchTech Group B.V. | Use of chicken embryo meat |
| NL2023582B1 (en) * | 2019-07-29 | 2021-02-22 | Hatchtech Group Bv | Use of chicken embryo meat |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100277095B1 (en) | Testosterone-enhancing composition and its manufacturing method | |
| ES2312430T3 (en) | STANDARD COMPOSITION OF THE CIRCADIAN RHYTHM. | |
| JP4653400B2 (en) | Diabetes composition | |
| US20120021088A1 (en) | Oral use | |
| KR20100015595A (en) | Novel use of hydroxytyrosol and olive extracts/concentrates containing it | |
| JPWO2008069276A1 (en) | Cancer therapeutic agent and carcinogenesis inhibitor | |
| BR112019008687B1 (en) | COMPOSITION COMPRISING A WATER SOLUBLE TOMATO EXTRACT (WSTE) | |
| WO2018039755A1 (en) | Zinc- and quercetin-based pharmaceutical formulation for the production of antiviral medication effective for dengue and zika | |
| AU2022242810A1 (en) | Paraxanthine-based compositions for promoting weight loss | |
| CA2197050A1 (en) | Anti-cancer agents derived from fertilized incubated shell eggs | |
| ES2808626T3 (en) | Composition for the use of cinnamaldehyde and zinc to manage weight | |
| WO2012116992A2 (en) | Oral use | |
| US20040097429A1 (en) | Method for the reduction of the mammalian appetite | |
| JP3860133B2 (en) | Diet food | |
| JP2011116670A (en) | Method for eliminating malaria, sleeping sickness, aids and hepatitis c and apparatus therefor | |
| Tarantul et al. | Turmeric (lat. Curcuma) | |
| JP2002187846A (en) | Composition, food products, antiarthritic agent and antirheumatic agent or feed including the same | |
| JP2012024016A (en) | Method for exterminating malaria, sleeping sickness, aids, and hepatitis c, and apparatus therefor | |
| JP2011012021A (en) | Blood sugar-controlling composition | |
| KR20080090101A (en) | Nutraceuticals using marine, plant capsosiphon fulvescens(mesangi) and its process | |
| WO2018101231A1 (en) | Composition for sympathetic nerve activation | |
| JP3345650B2 (en) | Hypertension inhibitor | |
| WO2011034006A1 (en) | Composition for lowering blood uric acid level | |
| KR20190086871A (en) | Composition for suppression of liver damage due to alcohol comprising Scapharca broughtonii extract as effective component | |
| JP2012170435A (en) | Method for exterminating malaria, narcolepsy, aids, and hepatitis c, and device therefor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Dead |